Pablo Florenzano

Pablo Florenzano

Auto-generated profile, based on publicly available information

Pablo Florenzano

Department of Endocrinology, School of Medicine, Pontificia Universidad Católica de Chile , Santiago 8320165

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 June 2020 in Calcified Tissue International
Verified
Journal Article
Closed access
PDF file
PFPablo Florenzano
Pablo Florenzano
IHIris R. Hartley
Iris R. Hartley
MJMacarena Jimenez
Macarena Jimenez
KRKelly Roszko
Kelly Roszko
RGRachel I. Gafni
Rachel I. Gafni
MCMichael T. Collins
Michael T. Collins

1 December 2017 in Bone Reports
Verified
Journal Article
Open access
PFPablo Florenzano
Pablo Florenzano
RGRachel I. Gafni
Rachel I. Gafni
MCMichael T. Collins
Michael T. Collins
Tumor-induced osteomalacia (TIO) is a rare paraneoplastic syndrome clinically characterized by bone pain, fractures and muscle weakness. It is caused by tumoral overproduction of fibroblast growth factor 23 (FGF23) that acts primarily at the proximal renal tubule, decreasing phosphate reabsorption and 1α-hydroxylation of 25 hydroxyvitamin D, thus producing hypophosphatemia and osteomalacia. Lesions are typically small, benign mesenchymal tumors that may be found in bone or soft tissue, anywhere in the body. In up to 60% of these tumors, a fibronectin-1(FN1) and fibroblast growth factor receptor-1 (FGFR1) fusion gene has been identified that may serve as a tumoral driver. The diagnosis is established by the finding of acquired chronic hypophosphatemia due to isolated renal phosphate wasting with concomitant elevated or inappropriately normal blood levels of FGF23 and decreased or inappropriately normal 1,25-OH2-Vitamin D (1,25(OH)2D). Locating the tumor is critical, as complete removal is curative. For this purpose, a step-wise approach is recommended, starting with a thorough medical history and physical examination, followed by functional imaging. Suspicious lesions should be confirmed by anatomical imaging, and if needed, selective venous sampling with measurement of FGF23. If the tumor is not localized, or surgical resection is not possible, medical therapy with phosphate and active vitamin D is usually successful in healing the osteomalacia and reducing symptoms. However, compliance is often poor due to the frequent dosing regimen and side effects. Furthermore, careful monitoring is needed to avoid complications such us secondary/tertiary hyperparathyroidism, hypercalciuria, and nephrocalcinosis. Novel therapeutical approaches are being developed for TIO patients, such as image-guided tumor ablation and medical treatment with the anti-FGF23 monoclonal antibody KRN23 or anti FGFR medications. The case of a patient with TIO is presented to illustrate the importance of adequate and appropriate evaluation of patients with bone pain and hypophosphatemia, as well as an step-wise localization study of patients with suspected TIO.

22 May 2019 in Journal of Bone and Mineral Research
Verified
Journal Article
Open access
PDF file
GPGeorgios Z Papadakis
Georgios Z Papadakis
GMGeorgios Manikis
Georgios Manikis
AKApostolos H Karantanas
Apostolos H Karantanas
PFPablo Florenzano
Pablo Florenzano
UBUlas Bagci
Ulas Bagci
ABAlison M Boyce
Alison M Boyce
Fibrous dysplasia (FD) is a mosaic skeletal disorder resulting in fractures, deformity, and functional impairment. Clinical evaluation has been limited by a lack of surrogate endpoints capable of quantitating disease activity. The purpose of this study was to investigate the utility of 18F-NaF PET/CT imaging in quantifying disease activity in patients with FD. Fifteen consecutively evaluated subjects underwent whole-body 18F-NaF PET/CT scans, and FD burden was assessed by quantifying FD-related 18F-NaF activity. 18F-NaF PET/CT parameters obtained included (i) SUVmax (standardized uptake value [SUV] of the FD lesion with the highest uptake); (ii) SUVmean (average SUV of all 18F-NaF–positive FD lesions); (iii) total volume of all 18F-NaF–positive FD lesions (TV); and (iv) total FD lesion activity determined as the product of TV multiplied by SUVmean (TA = TV × SUVmean) (TA). Skeletal outcomes, functional outcomes, and bone turnover markers were correlated with 18F-NaF PET/CT parameters. TV and TA of extracranial FD lesions correlated strongly with skeletal outcomes including fractures and surgeries (p values ≤ 0.003). Subjects with impaired ambulation and scoliosis had significantly higher TV and TA values (P < 0.05), obtained from extracranial and spinal lesions, respectively. Craniofacial surgeries correlated with TV and TA of skull FD lesions (P < 0.001). Bone turnover markers, including alkaline phosphatase, N-telopeptides, and osteocalcin, were strongly correlated with TV and TA (P < 0.05) extracted from FD lesions in the entire skeleton. No associations were identified with SUVmax or SUVmean. Bone pain and age did not correlate with 18F-NaF PET/CT parameters. FD burden evaluated by 18F-NaF-PET/CT facilitates accurate assessment of FD activity, and correlates quantitatively with clinically-relevant skeletal outcomes. © 2019 American Society for Bone and Mineral Research.

23 December 2021 in Journal of Bone and Mineral Research
Verified
Journal Article
Open access
PDF file
FAFahad Aljuraibah
Fahad Aljuraibah
JBJustine Bacchetta
Justine Bacchetta
Maria Luisa BrandiMaria Luisa Brandi
Maria Luisa Brandi
PFPablo Florenzano
Pablo Florenzano
MJMuhammad K Javaid
Muhammad K Javaid
CWCarsten A Wagner
Carsten A Wagner
Because of their rarity, diseases characterized by chronic hypophosphatemia can be underrecognized and suboptimally managed, resulting in poor clinical outcomes. Moreover, serum phosphate may not be measured routinely in primary care practice. Authors participated in several working sessions to advance the understanding of phosphate homeostasis and the causes, consequences, and clinical implications of chronic hypophosphatemia. Phosphate levels are regulated from birth to adulthood. Dysregulation of phosphate homeostasis can result in hypophosphatemia, which becomes chronic if phosphate levels cannot be normalized. Chronic hypophosphatemia may be underrecognized as serum phosphate measurement is not always part of routine analysis in the primary care setting and results might be misinterpreted, for instance, due to age-specific differences not being accounted for and circadian variations. Clinical consequences of chronic hypophosphatemia involve disordered endocrine regulation, affect multiple organ systems, and vary depending on patient age and the underlying disorder. Signs and symptoms of chronic hypophosphatemic diseases that manifest during childhood or adolescence persist into adulthood if the disease is inadequately managed, resulting in an accumulation of clinical deficits and a progressive, debilitating impact on quality of life. Early identification and diagnosis of patients with chronic hypophosphatemia is crucial, and clinical management should be started as soon as possible to maximize the likelihood of improving health outcomes. Furthermore, in the absence of a universally accepted description for “chronic hypophosphatemia,” a definition is proposed here that aims to raise awareness of these diseases, facilitate diagnosis, and guide optimal phosphate management strategies by improving monitoring and assessment of patient response to treatment. © 2021 The Authors. Journal of Bone and Mineral Research published by Wiley Periodicals LLC on behalf of American Society for Bone and Mineral Research (ASBMR).

1 December 2020 in Journal of Bone and Mineral Research
Verified
Journal Article
Closed access
IHIris R. Hartley
Iris R. Hartley
RGRachel I. Gafni
Rachel I. Gafni
KRKelly L. Roszko
Kelly L. Roszko
SBSydney M. Brown
Sydney M. Brown
LDLuis Fernandez de Castro Diaz
Luis Fernandez de Castro Diaz
PFPablo Florenzano
Pablo Florenzano

17 February 2025 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Open access
DADalal Ali
Dalal Ali
TCThomas Carpenter
Thomas Carpenter
EIErik A Imel
Erik A Imel
LWLeanne M Ward
Leanne M Ward
NANatasha M. Appelman-Dijkstra
Natasha M. Appelman-Dijkstra
AKAliya A. Khan
Aliya A. Khan
Context: An International Working Group (IWG) developed new guidelines on the diagnosis, evaluation, management, and monitoring of X-linked hypophosphatemia (XLH) in children. Over the past 5 years, important advances have occurred in our understanding of the presentation, complications, and treatment of XLH. Methods: A group of 50 international experts in XLH from Canada, the United States, Europe, Asia, and South America, along with methodology experts and a patient partner, held 18 teleconference meetings in 2023-2024. These meetings addressed key issues regarding diagnosing, evaluating, managing, and monitoring XLH in children. Two systematic reviews were conducted to examine the impact of burosumab compared to conventional therapy (phosphate salts and active vitamin D) or no therapy, and to assess the impact of conventional therapy vs no therapy on patient-important outcomes. The certainty of evidence was evaluated using the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) methodology. Additionally, narrative reviews were completed on XLH diagnosis and the role of genetic testing, and an expert clinical practice survey informed the monitoring recommendations. Outcomes: An approach to establishing the diagnosis of XLH is presented. GRADEd recommendations were developed on treatment strategies for XLH in children. Monitoring recommendations, GRADEd as weak with very low certainty, were based on clinical practice survey of the IWG experts. The guidelines also addressed dental complications and proposed potential strategies to mitigate them. Conclusion: These clinical practice guidelines provide an update of the current evidence on the diagnosis and management of XLH and provide a comprehensive guidance for multidisciplinary healthcare professionals involved in the care of children with XLH.